Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa

Curr Opin Ophthalmol. 2008 Sep;19(5):414-21. doi: 10.1097/ICU.0b013e32830b1539.


Purpose of review: The goal of this review is to update ophthalmologists and orbital and adnexal specialists with the emerging role of targeted monoclonal antibody therapy and radioimmunotherapy for orbital and adnexal non-Hodgkin's lymphoma and other lymphoproliferative disorders of the orbit.

Recent findings: Rituximab as monotherapy for indolent lymphoma of the orbit and conjunctiva may be associated with good initial response, but the risk of distant relapse is about 50%. Rituximab may be used in combination with conventional chemotherapy, and such combination therapy may be associated with a higher durable response rate and improved progression-free survival compared with chemotherapy alone. Radioimmunotherapy using targeted monoclonal antibodies with radioactive conjugates is also associated with a more durable response rate than monotherapy with rituximab alone and may be an alternative for treatment of ocular adnexal lymphoma. Radioimmunoconjugates are associated with transient pancytopenia during the first 3 months after treatment. Rituximab monotherapy may be considered as an alternative to systemic steroids for treatment of orbital benign lymphoid hyperplasia.

Summary: Targeted monoclonal antibody therapy is an intriguing new modality for treatment of orbital, eyelid, or conjunctival lymphoma and can be used in combination with radioimmunotherapy or standard chemotherapy for a more durable response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Conjunctival Neoplasms / diagnosis
  • Conjunctival Neoplasms / drug therapy
  • Conjunctival Neoplasms / radiotherapy
  • Conjunctival Neoplasms / therapy*
  • Eyelid Neoplasms / diagnosis
  • Eyelid Neoplasms / drug therapy
  • Eyelid Neoplasms / radiotherapy
  • Eyelid Neoplasms / therapy*
  • Humans
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / radiotherapy
  • Lymphoma, Non-Hodgkin / therapy*
  • Magnetic Resonance Imaging
  • Orbital Neoplasms / diagnosis
  • Orbital Neoplasms / drug therapy
  • Orbital Neoplasms / radiotherapy
  • Orbital Neoplasms / therapy*
  • Positron-Emission Tomography
  • Radioimmunotherapy*
  • Rituximab


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab